



 [Update Your Profile](#)

France Carrier, PhD

Academic Title:

Professor

Primary Appointment:

Radiation Oncology

Email:

fcarr001@umaryland.edu

Location:

Bressler Research Building, 10-037

Phone (Primary):

(410) 706-5105

Fax:

(410) 706-3260

[Download CV](#)

Education and Training

University of Quebec at Trois-Rivières, Québec, Canada, B.Sc./Medical Biology, 1983

University of Montreal, M.Sc./ Clinical Sciences/Biochemistry, 1986

University of Montreal, Ph.D./Clinical Sciences/Biochemistry, 1988

Postdoctoral Fellow, Biotechnology Research Institute, National Research Council, Montreal Canada, Protein Engineering, 1988-1989

Guest Researcher, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, Developmental Pharmacology, 1989-1991

Visiting Associate, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, Laboratory of Molecular Pharmacology, 1991-1998

Biosketch

Dr. Carrier is an internationally renowned basic and translational cancer researcher, with specific training and expertise in genotoxic stress response and cancer progression. Her basic cancer research studies include activation of stress-responsive RNA binding proteins and their specific involvement in regulating protein translation in cancer cells. Her work has established hnRNP A18^{CIRP} as a key regulator of protein translation in cancer cells by delineating its mechanism of action through specific signature motifs located in the 3' UTR of its targeted transcripts. Her lab is currently funded by the National Institutes of Health.

Her translational cancer research include her pioneered work on demonstrating the efficiency of a new class of anticancer drugs, histone deacetylase inhibitors, in combination with conventional anticancer drugs such as VP-16, ellipticine, doxorubicin, and cisplatin. This led to a recently completed Phase 1 clinical trial at her institution for relapsed and/or acute leukemia and myelodysplastic syndromes. She also actively contributes to the development of new clinical trials in radiation oncology, where her knowledge of the genotoxic stress response at the cellular and molecular levels complements new investigative clinical approaches with Low-Dose Fractionated Radiation Therapy (LDFRT) and radiation-stimulated immune response.

Dr. Carrier holds four patents, her publications have been cited over 7,000 times, including 13 papers with more than 100 citations each. She has lectured around the world, chair and co-chair numerous sessions at national and international cancer research meetings and served on the editorial boards of prestigious journals such as Cancer Research. Throughout her career, she has mentored a large number of talented scientists to pursue careers in the academics, government and industries related to cancer research.

Research/Clinical Keywords

Melanoma, gastric cancer, low dose radiation, histone deacetylase inhibitors

Highlighted Publications

Kim, M.S., Blake, M., Baek, J.H., Kohlhagen, G., Pommier, Y., and Carrier, F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. *Cancer Research*, 63, 7291-7300, 2003. PMID: 14612526

Gojo, I, Tan, M, Fang, H-B, Sadowska, M., Lapidus, R., Baer, M.R., Carrier, F., Beumer, J.H., Anyang, B.N., Srivastava, R.K., Espinoza-Delgado, I. and Ross, D.D. Translational phase I trial of vorinostat combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia. *Clinical Cancer Res.* Apr 1;19(7):1838-1851. Epub 2013 Feb 12., 2013. PMID: 23403629

Diss, E, Nalabothula, N, Nguyen, DM, Chang, ET., Kwok, Y., Carrier, F. Vorinostat^{saha} promotes hyper-radiosensitivity in wild type p53 human glioblastoma cells. *Journal of Clinical Oncology and Research, JSM Clin Oncol Res* 2(1): 1004, 1-9, 2014. PMID: 25379568

Nguyen, D.M., Parekh, P.R., Chang, E.T., Sharma, N.K., Carrier, F. Contribution of Dual Oxidase 2 (DUOX2) to hyper radiosensitivity in human Gastric Cancer cells. *Radiation Research*, 184, 151 - 160, 2015. PMID: 26207686

Chang, E.T., Parekh, P.R., Yang, Q., Nguyen, D.M., and Carrier, F. The heterogenous ribonucleoprotein A18 (hnRNP A18) promotes tumor growth by increasing protein translation of selected transcripts in cancer cells. *Oncotarget*, (Vol.7) No 9, p. 10578-10593, 2016 Jan 25, Epub ahead of print. PMID: 26824423

 [Update Your Profile](#)